FDA Submission Guide

FDA Medical Device Classification and Pathways

Class I Devices

• 510(k) Exempt - Most Class I devices
• General Controls apply (21 CFR 820)
• FDA registration required
• Device listing mandatory

Class II Devices

• 510(k) Clearance - Premarket notification
• General + Special Controls apply
• Predicate device identification required
• Substantial equivalence demonstration

Class III Devices

• PMA (Premarket Approval) - Full safety and effectiveness review
• IDE (Investigational Device Exemption) for clinical studies
• Clinical data typically required
• Post-market surveillance obligations

De Novo Classification

• Novel devices without predicate
• Low to moderate risk profile
• Creates new device classification
• Special controls development

Submission Pathways and Requirements

1. 510(k) Premarket Notification

Traditional 510(k)

• Predicate device comparison
• Performance testing documentation
• Software documentation (if applicable)
• Labeling and indications for use

Special 510(k)

• Modifications to cleared devices
• Design controls documentation
• Risk analysis of changes
• Performance validation

Abbreviated 510(k)

• Guidance document compliance
• Recognized standards conformance
• Special controls adherence
• Reduced documentation requirements

2. PMA (Premarket Approval)

Clinical Investigation Requirements

• IDE study protocol approval
• GCP compliance documentation
• Clinical study reports
• Statistical analysis plans

Manufacturing Information

• ISO 13485 QMS compliance
• Manufacturing process validation
• Facility inspection readiness
• Supply chain documentation

3. De Novo Classification Request

Risk-based Classification

• Benefit-risk profile analysis
• Predicate device absence justification
• Special controls recommendations
• Clinical evidence strategy

FDA Submission Process

Pre-Submission Activities

1. Q-Sub Meeting - Pre-submission consultation
2. Classification determination confirmation
3. Predicate device identification and analysis
4. Testing strategy development and validation
5. FDA guidance review and compliance assessment

Submission Preparation

1. Technical documentation compilation per FDA format
2. Quality system documentation and readiness
3. Clinical evidence compilation (if required)
4. Labeling and indications for use finalization
5. eCopy submission preparation

FDA Review Process

1. Administrative review (15 days for completeness)
2. Substantive review (90 days for 510(k), 180 days for PMA)
3. Additional information requests and responses
4. FDA questions and clarifications
5. Clearance/approval or denial decision

Special Considerations

Software as Medical Device (SaMD)

• Software documentation per FDA guidance
• Cybersecurity considerations and risk management
• Software lifecycle process documentation
• Change control procedures

Combination Products

• OPDP assignment determination
• Lead center coordination
• Intercenter agreement requirements
• Combination product specific guidance

HIPAA Compliance

• Protected Health Information safeguards
• Business associate agreements
• Risk assessment and management
• Breach notification procedures

Quality System Requirements

21 CFR Part 820 (QMSR — ISO 13485:2016 incorporated by reference)

⚠️ STATUS — QMSR transition (effective 2026-02-02): FDA's QMSR final rule (89 FR 7496) amended 21 CFR Part 820 to incorporate ISO 13485:2016 by reference and removed the legacy QSR subsection structure. Cite the ISO 13485 clauses — the legacy 820.x numbers below are historical index only.

• Design and development — ISO 13485 §7.3 (legacy QSR 820.30, historical)
• Document control — ISO 13485 §4.2.4 (legacy QSR 820.40, historical)
• Management responsibility — ISO 13485 §5 (legacy QSR 820.20, historical)
• Corrective and preventive action — ISO 13485 §8.5.2/§8.5.3 (legacy QSR 820.100, historical)

Key Performance Metrics

• Review timeline adherence and predictability
• First-time clearance rates and success factors
• Additional information request frequency
• Post-market compliance effectiveness
• FDA inspection readiness and outcomes